This brand name is authorized in Nigeria.
The drug BEDIXA contains one active pharmaceutical ingredient (API):
1
|
UNII
7S5I7G3JQL - DEXAMETHASONE
|
|
Dexamethasone is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. It has an approximately 7 times greater anti-inflammatory potency than prednisolone, another commonly prescribed corticosteroid. At high doses it reduces the immune response. |
|
This drug has been approved in Nigeria as follows:
| Identifier | Form | Presentation | Description | Approval |
|---|---|---|---|---|
| B4-0703 | Tablet | Bedixa 0.5 mg Tablets TAB 0.5 mg 10 x 10's (in PVC/Alu blisters) | Tablet. White, round and flat caplets with bevelled edges | 27/05/2021 |
| B4-0718 | Tablet | Bedixa Tablet TAB 1 mg 10 x 10's (in PVC/Alu blisters) | Tablet White, round and flat caplets with bevelled edges | 29/03/2021 |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| NG | Registered Drug Product Database | B4-0703, B4-0718 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.